Aristo Bio-Tech and Lifescience SME is a publicly traded company that specializes in the development and manufacture of innovative biotech and life science products. The company recently launched an Initial Public Offering (IPO) to raise capital and broaden its shareholder base.
Aristo Bio-Tech and Lifescience SME has a strong reputation in the industry for developing cutting-edge products that improve the quality of life for people around the world. The company’s portfolio of products includes a range of diagnostic kits, reagents, and other biotech tools that are used in medical research and clinical settings.
The company’s decision to go public is a significant milestone, as it will allow Aristo Bio-Tech and Lifescience SME to expand its operations and accelerate the development of new products. The proceeds from the IPO will be used to fund research and development, as well as to expand the company’s manufacturing and distribution capabilities.
One of the key factors that sets Aristo Bio-Tech and Lifescience SME apart from its competitors is its strong team of scientists and researchers. The company’s research and development efforts are led by a group of highly experienced and accomplished professionals who have a deep understanding of the biotech and life science industries.
Aristo Bio-Tech and Lifescience SME is well-positioned to capitalize on the growth opportunities in the biotech and life science markets. The company’s innovative products and strong leadership team are expected to drive its continued success in the years to come.
Investors who are interested in learning more about Aristo Bio-Tech and Lifescience SME and its IPO can find more information on the company’s website or through its financial advisor.
Overall, Aristo Bio-Tech and Lifescience SME IPO can be a great opportunity for investors to participate in the growth of a company that is at the forefront of innovative biotech and life science products, and that has a solid management team and a great vision.
As with any investment opportunity, it is important for investors to conduct their own research, seek professional advice, and consider their own risk tolerance before investing.
Aristo Bio-Tech and Lifescience SME IPO Details
SME IPO Issue Opening Date: | 16th Jan 2023 |
SME IPO Issue Closing Date: | 19th Jan 2023 |
SME IPO Issue Price: | ₹72 Per Share |
DRHP: | View DRHP |
RHP: | View RHP |
IPO Listing At: | NSE SME |
Retail Quota: | 50% of the Net Issue% |
SME IPO Issue Type: | Fixed Price Issue |
SME IPO Issue Size: | ₹13.05Cr |
Fresh Issue: | ₹13.05Cr |
Face Value: | ₹10 Per Equity Share |
SME IPO Discount: | TBD |
Promoter Holding Pre IPO: | 100.00% |
Promoter Holding Post IPO: | 73.37% |
Aristo Bio-Tech and Lifescience SME IPO Strengths
- Experienced management and a well-trained employee base
- Existing client relationship
- Scalable Business Model
- Cost effective production and timely fulfillment of orders